Helix BioPharma (TSE:HBP) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Helix BioPharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor from Laevoroc Immunology AG, enhancing its immune-oncology portfolio. This transaction will involve issuing 16.5% of Helix’s shares to acquire intellectual property and assets, pending regulatory approval. The move aims to expand Helix’s pipeline with promising therapeutic candidates for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
